Tengion appoints John Miclot president and CEO
This article was originally published in Scrip
Tengion, a clinical-stage biotech company, has appointed John Miclot president and CEO. Mr Miclot was most recently an executive-in-residence at Warburg Pincus, and prior to that was president and CEO of CCS Medical, a company owned by Warburg Pincus. He served in this role from 2008 until the completion of a financial restructuring of the company in 2010.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.